2d
Hosted on MSNDown -8.52% in 4 Weeks, Here's Why Sarepta Therapeutics (SRPT) Looks Ripe for a TurnaroundSarepta Therapeutics (SRPT) has been beaten down lately with too much selling pressure. While the stock has lost 8.5% over ...
Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...
11h
Hosted on MSNSolid Biosciences Soars 32% on Trial Data: 189% Upside from Here?Shares of biotech company Solid Biosciences (NASDAQ: SLDB) skyrocketed on Feb. 18 after the firm released key clinical data.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it ...
The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth ...
Eli Lilly has been a terrific stock to own for the past five years, thanks to its excellent clinical and regulatory progress.
Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...
State of Alaska Department of Revenue reduced its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 1.3% ...
TD Cowen analyst Ritu Baral maintained a Buy rating on Pliant Therapeutics (PLRX – Research Report) today. The company’s shares closed last ...
TD Cowen analyst Ritu Baral reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $60.00.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results